The relationship between ACE/AGT gene polymorphisms and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes

Yong-chao Qiao\textsuperscript{1}\textsuperscript{a}, Min Wang\textsuperscript{2,3}, Yan-hong Pan\textsuperscript{2}, Xiao-xi Zhang\textsuperscript{2,3}, Fang Tian\textsuperscript{1}, Yin-ling Chen\textsuperscript{2,3} and Hai-lu Zhao\textsuperscript{1,2,3}

Abstract

Aims: This study aims to investigate the association between renin-angiotensin system gene polymorphism and diabetic retinopathy (DR) in Chinese patients with type 2 diabetes.

Methods: We consecutively included 1491 patients for the assessment of ACE I/D and AGT M/T gene polymorphisms in 345 DR cases and 1146 patients without retinopathy (DNR). Albuminuria was defined by urine albumin creatinine ratio and albumin excretion rate.

Results: Compared with the NDR patients, the DR cases displayed a higher proportion of diabetic nephropathy (32.68\% vs. 6.52\%, $\chi^2 = 150.713$, $p < 0.001$). The DR cases and DNR individuals did not differ in the frequency of genotypes and alleles of ACE I/D and AGT M/T (all $p > 0.05$). Intriguingly, DR patients with obesity showed higher frequency of DD ($\chi^2 = 4.181$, $p = 0.041$), but no significant difference exists in the other stratified BMI and hypertension analyses (all $p > 0.05$). Binary logistic regression displays that the association of the ACE and AGT gene polymorphisms in DR patients is not significant after adjusting for confounding covariates in all the comparisons.

Conclusions: The ACE and AGT gene polymorphisms are not associated with the progress of diabetes developing into retinopathy in Chinese patients with type 2 diabetes. However, more investigations are needed to further prove the association.

Keywords
T2DM, diabetic retinopathy, ACE, AGT, rennin-angiotensin system

Date received: 30 September 2016; accepted: 14 December 2017

Introduction

Diabetic retinopathy (DR) is one of the most devastating microvascular complications of diabetes mellitus\textsuperscript{1} and remains a major cause of visual morbidity in developed and developing countries.\textsuperscript{2,3} Epidemiological studies have shown that DR exists in almost all individuals with long-standing type 1 diabetes mellitus (T1DM), and approximately 60\% of patients with type 2 diabetes mellitus (T2DM) develop retinopathy.\textsuperscript{4} In addition to the increased classic cardiovascular risk factors in diabetes, genetic factors may contribute to the development of these complications. Indeed, monozygotic twins with T2DM show a substantial concordance for the development of DR, suggesting that genetic factors may have a role in DR.\textsuperscript{5} Several genetic markers have been studied,\textsuperscript{6–10} but up to now, no main genetic locus has been identified.

---

\textsuperscript{1}Department of Immunology, Xiangya School of Medicine, Central South University, China

\textsuperscript{2}Center for Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilan Medical University, China

\textsuperscript{3}Department of Immunology, Faculty of Basic Medicine, Guilan Medical University, China

Corresponding author: Hai-Lu Zhao, Center for Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilan Medical University, Huan Cheng North 2nd Road 109, Guilan S41004, China. Email: zhaohailu9@126.com
The renin-angiotensin system (RAS) consists of renin, angiotensinogen (AGT), angiotensin-converting enzyme (ACE), ACE2, angiotensin II type 1 receptor (AT1R) and AT2R. In human physiology, RAS is fundamental to blood pressure regulation; as such, each component is potentially involved in the etiology of the polygenic disorder known as primary hypertension. AGT is converted to angiotensin I by renin, and subsequently into angiotensin II by ACE. ACE plays an important role in the regulation of systemic and renal vascular circulation by converting angiotensin I into vasoconstrictor molecule angiotensin II. Higher levels of renin activity and ACE activity during the course of diabetes result in an excess of angiotensin II in the eye, abnormally constricted retinal arterioles, elevated local intravascular blood pressure, reduced retinal blood flow, increased permeability of retinal blood vessels, and ocular neovascularization. Interestingly, the ACE gene intron 16 insertion/deletion (I/D) polymorphism accounts for about one-half of the phenotypic variance in plasma ACE levels.

In recent years, several groups of researchers have focused on the relationship between RAS and DR. However, their findings are inconsistent. Recently, we have shown an association of diabetic glomerulosclerosis with immunoreactivity of ACE and AGT. Here we report that the ACE and AGT gene polymorphisms might not have a significant effect on DR in a group of Chinese T2DM patients.

**Participants, materials and methods**

**Participants and clinical measurements**

In this cross-sectional clinical-genetic association study, we consecutively recruited 1491 T2DM patients. Among them, 345 had been diagnosed as DR and 1146 were diagnosed as diabetic non-retinopathy (DNR). Cases clinically diagnosed and sampled from the database of the university-affiliated hospital before 2012 participated in this study. Patients with a controlled diet and the use of antihypertensive drugs and RAS blocking were excluded. Before taking blood samples, we informed each patient about the guidelines of the institutional review board of the Guilin Medical University (GLMC191211HL). All cases were initially diagnosed with T2DM by a qualified endocrinologist. DM was diagnosed and classified according to 1985 World Health Organization (WHO) criteria. Patients underwent detailed eye examination with ophthalmoscopy, funduscopy and fundus photography to assess DR. All patients underwent complete physical examination including body mass index (BMI), fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), lipid profile (triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), albumin-to-creatinine ratio (ACR) and albumin excretion rate (AER) according the previous report.

**ACE and AGT genotyping**

Genomic DNA of patients was extracted using protocols reported in our previous article. Polymerase chain reaction (PCR) was used to determine the ACE gene I/D and AGT gene methionine (M)/threonine T polymorphisms through primers flanking the polymorphic region of intron 16 and 354 bp of exon 2, respectively. The primers used in this study were 5′-CTGGAGACCACCTCCCATCCTTTTCT-3′ and 5′-GATGTGGCCATCACATTGCTCAGAT-3′ for ACE I/D, and were 5′-CAGGGTGCATGCTCCACACTG GACCCC-3′ and 5′-CCGTGTTGCGAGGCTGCTGCT CTTCT-3′ for AGT M/T gene polymorphism, respectively. PCR amplification revealed a 190 bp fragment (ACE D allele) and/or a 490 bp fragment (ACE I allele), and a 266 bp fragment (AGT M235 allele) and/or a 303 bp fragment (AGT 235T allele). Genotyping for the ACE gene I/D and AGT gene M/T polymorphism followed the methods described in our recent publication.

**Definitions and calculations**

Visual acuity was assessed systematically by specialist ophthalmologists who determined the presence and graded the severity of DR according to the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale. DR patients included nonproliferative and proliferative DR, and DM patients without retinopathy were defined as controls. Hypertension was defined as an average blood pressure ≥ 140/90 mm Hg on at least three different occasions at rest state or by the presence of antihypertensive treatment.

Renal status was defined by AER and ACR: normoalbuminuria (AER < 20 μg/min or ACR < 30 mg/g), microalbuminuria (20 ≤ AER < 200 μg/min or 30 ≤ ACR < 300 mg/g), macroalbuminuria (AER ≥ 200 μg/min or ACR ≥ 300 mg/g). BMI was derived according to the following formula: BMI = body weight (in kilograms)/square of the height (in meters). According to the BMI value, patients were divided into an obesity group (BMI ≥ 25 kg/m²), an overweight group (23 kg/m² ≤ BMI < 25 kg/m²), a normal group (18.5 kg/m² ≤ BMI < 23 kg/m²) and a lean group (BMI < 18.5 kg/m²); because of the small sample size of overweight and lean patients, we explored the distribution of genotypes and alleles only in obese and normal patients.

**Statistical analysis**

The data in this study were expressed as mean ± standard deviation (SD), median (interquartile range) or percentage, as appropriate. If the alleles were in Hardy-Weinberg equilibrium, the χ² test was performed to compare the genotype
Table 1. Clinical characteristic of 1491 patients and concordance between DR and diabetic nephropathy.

|                          | Total   | DR         | DNR         | p       |
|--------------------------|---------|------------|-------------|---------|
| n                        | 1491    | 345        | 1146        |         |
| Age (years)              | 53.42±13.60 | 60.08±11.34 | 51.42±13.59 | <0.001a |
| Male (%)                 | 603 (40.44) | 148 (42.90) | 455 (39.70)  | 0.289b  |
| Smoker (%)               | 194 (13.01) | 37 (10.72)  | 157 (13.70)  | 0.150b  |
| Age at onset (years)     | 47.42±13.95 | 50.80±13.30 | 46.40±13.98  | <0.001a |
| Duration of diabetes (years) | 5.50±6.4 | 8.97±7.13 | 4.45±6.42  | <0.001a |
| BMI (kg/m²)              | 24.78±3.74 | 24.36±3.30 | 24.91±3.85  | 0.009a  |
| C-peptide                | 1.74 (1.00–2.84) | 1.92 (0.95–2.90) | 1.70 (1.02–2.84) | 0.737a  |
| Hypertension (%)         | 277 (18.60) | 107 (31.01) | 170 (14.85)  | <0.001b |
| SBP (mmHg)               | 133.55±22.52 | 145.52±24.76 | 129.94±20.09 | <0.001a |
| DBP (mmHg)               | 80.15±11.41 | 82.94±13.34 | 79.31±10.62  | <0.001a |
| HbA1c (%)                | 7.86±1.98  | 8.70±2.18  | 7.61±1.84   | <0.001a |
| FPG (mmol/l)             | 8.82±3.53  | 10.10±4.36 | 8.43±3.14  | <0.001a |
| TG (mmol/l)              | 1.35 (0.92–2.00) | 1.44 (1.01–2.21) | 1.30 (0.90–1.95) | 0.002c |
| TC (mmol/l)              | 5.49±1.26  | 5.76±1.35  | 5.41±1.22  | <0.001a |
| LDL-C (mmol/l)           | 3.40 (2.80–4.00) | 3.60 (2.90–4.30) | 3.30 (2.70–4.00) | 0.982a |
| HDL-C (mmol/l)           | 1.21 (1.02–1.44) | 1.18 (0.99–1.43) | 1.21 (1.03–1.44) | 0.373a |
| Plasma urea (mmol/l)     | 5.96±3.15  | 7.56±4.83  | 5.47±2.21  | <0.001c |
| Plasma creatinine (μmol/l) | 78.82±44.92 | 99.61±73.85 | 72.55±28.55 | <0.001c |
| ACR (mg/g)               | 1.82 (0.88–6.97) | 9.02 (1.79–68.58) | 1.46 (0.80–3.79) | <0.001c |
| AER (μg/min)             | 9.35 (5.57–29.57) | 50.75 (9.10–383.82) | 9.11 (5.48–25.58) | <0.001c |

Concordance between DR and diabetic nephropathy defined by ACR/AER

Participants were stratified according to normoalbuminuria, microalbuminuria and macroalbuminuria. According to ACR or AER, microalbuminuria and macroalbuminuria were defined as diabetic nephropathy. As shown in Table 1, the DR cases contrasted with DNR patients in having a

Results

Characteristics of patient samples and clinical findings

In this study, a total of 1491 patients with T2DM were enrolled: 345 individuals with DR and 1146 diabetic patients without retinopathy. Successful genotyping for the ACE I/D and AGT M/T gene polymorphisms were obtained from 1485 patients (344 DR cases) and 1245 (293 DR cases) participants, respectively. The demographic characteristics of T2DM patients with DR are displayed in Table 1. Compared with DNR patients, the DR cases were older (p < 0.001), had a higher proportion of hypertension (p < 0.001), a higher proportion of diabetes (p < 0.001), higher levels of HbA1c (p < 0.001), FPG (p < 0.001), TC (p < 0.001), TG (p = 0.002), plasma urea (p < 0.001), plasma creatinine (p < 0.001), ACR (p < 0.001), AER (p = 0.011), BMI (p = 0.009), systolic blood pressure (SBP, p < 0.001) and diastolic blood pressure (DBP, p < 0.001).

Distribution of each polymorphism. For categorical variables, χ² tests were used to find out differences between groups. Differences in continuous variables were analyzed by Student’s t-test and one-way analysis of covariance in normal distribution, and Mann–Whitney U test was performed for abnormal distribution. To assess the association of disease with genotype, we used binary logistic regression analysis after adjusting for various factors. The p value < 0.05 was defined as statistically significant. Post-hoc power calculation was conducted by using the PS software (Power and Sample Size Calculation). Statistical analyses were performed using the SPSS program (SPSS version 15, SPSS Inc, Chicago, IL, USA).
significantly higher proportion of diabetic nephropathy ($\chi^2 = 150.713, p < 0.001$), which indicated a strong concordance between DR and diabetic nephropathy.

**The relation between ACE and AGT gene polymorphism and DR**

The genotype and allele frequencies of the $ACE$ I/D and $AGT$ M/T are shown in Table 2. Genotype frequencies in all groups are all in accordance with the Hardy-Weinberg equilibrium (all $p > 0.05$). Patients with the presence of retinopathy compared to the absence had no significant association with the frequency of $ACE$ genotype (DD vs. DI vs. II, $\chi^2 = 2.076, p = 0.160$) and $AGT$ genotype (MM vs. MT vs. TT, $\chi^2 = 1.576, p = 0.209$) (Table 2).

**Correction for confounding risk factors**

To address the confounding risk factors including BMI and hypertension, as displayed in Table 3, obese DR cases had significantly higher frequency of DD genotype ($\chi^2 = 4.181, p = 0.041$). In contrast, patients with normal BMI had similar RAS polymorphisms between the two groups relating to $ACE$ genotype and $AGT$ genotype (all $p > 0.05$), as shown in Table 4. No significant difference in the frequency of $ACE$ and $AGT$ genotypes and alleles relating to DR was displayed in the hypertensive and normotensive patients (all $p > 0.05$).

In binary logistic regression with groups (DNR vs. DR) as the dependent variable and age, age of onset, duration of diabetes, BMI, hypertension (%), HbA$_1c$, FPG, TG, TC, LDL-C, HDL-C, plasma urea, plasma creatinine, ACR, AER, and $ACE/AGT$ genotype as covariates, the association of the $ACE$ and $AGT$ gene polymorphisms with DR in T2DM patients still was not significant after adjusting for confounding factors (Table 5). Otherwise, no significant association was found between $ACE$ and $AGT$ gene polymorphisms and DR in all the stratified BMI and hypertension analyses after adjustment for covariates (all $p > 0.05$). The power value showed that the negative findings were partly due to lack of study power displayed in Table 2 and also displayed low value in other stratified BMI and hypertension analyses (data not shown).

## Discussion

In some population studies, the variants of the RAS gene have been associated with diabetes and its complications, and inhibition of RAS has prevented the risk of diabetes and its complications.$^{11}$ Most studies that evaluated the role of $ACE$ gene polymorphism with DR have different claims, yet few studies that assessed the $AGT$ gene polymorphism in T2DM patients with retinopathy displayed no significant association.$^{6,11}$

In this study, we analyzed the relationship between $ACE$ and $AGT$ gene polymorphism and T2DM patients with retinopathy. In a total of 1491 T2DM patients, we found that no significant difference existed between DR and DNR patients regarding $ACE$ or $AGT$ genotype or allele, and our negative findings are consistent with previous studies.$^{1,11,28}$ These findings indicate that the suggested role of genetics in predisposition to DR is unlikely to be mediated through differences in the DNA sequence of the $ACE$ or $AGT$ gene, and that the I/D and M/T

---

**Table 2. Association of RAS polymorphisms with DR in type 2 diabetes.**

| Genotype and allele | Total | DNR | DR | Comparison       | $p^a$ | Power value |
|--------------------|-------|-----|----|------------------|-------|-------------|
| **ACE**            |       |     |    |                  |       |             |
| DD                 | 166   | 124 (10.87) | 42 (12.21) | DD vs. DI+II | 0.489 | 0.112       |
| DI                 | 645   | 507 (44.43) | 138 (40.12) | DI vs. DD+II | 0.157 | 0.291       |
| II                 | 674   | 510 (44.70) | 164 (47.67) | II vs. DD+DI | 0.331 | 0.163       |
| **Total**          | 1485  | 1141 (100)  | 344 (100)   | DD vs. DI vs. II | 0.354 | –           |
| **D**              | 977   | 755 (33.09) | 222 (32.27) | D vs. I       | 0.689 | 0.261       |
| **I**              | 1993  | 1527 (66.91) | 466 (67.73) |                 |       |             |
| **Total**          | 2970  | 2282 (100)  | 688 (100)   |                 |       |             |
| **AGT**            |       |     |    |                  |       |             |
| MM                 | 30    | 25 (2.63)   | 5 (1.71)    | MM vs. MT+TT   | 0.369 | 0.118       |
| MT                 | 325   | 254 (26.68) | 71 (24.23)  | MT vs. MM+TT   | 0.404 | 0.128       |
| TT                 | 890   | 673 (70.69) | 217 (74.06) | TT vs. MM+MT   | 0.264 | 0.196       |
| **Total**          | 1245  | 952 (100)   | 293 (100)   | MM vs. MT vs.  | 0.437 | –           |
| **M**              | 385   | 304 (15.97) | 81 (13.82)  | M vs. T       | 0.209 | 0.234       |
| **T**              | 2105  | 1600 (84.03) | 505 (86.18) |                 |       |             |
| **Total**          | 2490  | 1904 (100)  | 586 (100)   |                 |       |             |

Data are shown as $n$ (percentage). $^a$Derived from the $\chi^2$ test.
Table 3. Association of RAS polymorphisms with BMI and DR in type 2 diabetes.

| Genotype and allele | Patients with BMI-defined obesity | | Patients with normal BMI | |
|---------------------|-----------------------------------|---|--------------------------|---|
|                     | Total DNR | DR | Comparison | p^a | Total DNR | DR | Comparison | p^a |
| ACE DD              | 128 | 100 | 69 (89.50) | 21 (15.67) | DD vs. DI+II | 0.041 | 96 | 75 | 21 (10.10) | 0.478 |
| DI                  | 278 | 268 | 226 (44.75) | 52 (38.81) | DI vs. DD+II | 0.217 | 364 | 279 | 85 (40.87) | 0.388 |
| II                  | 292 | 245 | 231 (45.74) | 61 (45.52) | II vs. DD+DI | 0.964 | 378 | 276 | 102 (49.04) | 0.189 |
| Total               | 693 | 552 | 505 (100) | 134 (100) | DD vs. DI vs. II | 0.101 | 838 | 630 | 208 (100) | 0.403 |
| D                   | 416 | 342 | 322 (71.88) | 94 (35.07) | D vs. I | 0.321 | 556 | 429 | 127 (30.53) | 0.310 |
| I                   | 862 | 120 | 688 (68.12) | 174 (64.93) | | 1120 | 831 | 289 (69.47) | |
| Total               | 1278 | 1050 | 1120 (100) | 268 (100) | | 1676 | 1260 | 416 (100) | |
| AGT MM              | 16 | 12 | 14 (3.38) | 2 (1.80) | MM vs. MT+TT | 0.390 | 14 | 11 | 3 (1.67) | 0.738 |
| MT                  | 133 | 107 | 107 (25.85) | 26 (23.42) | MT vs. MM+TT | 0.602 | 189 | 145 | 44 (24.44) | 0.460 |
| TT                  | 376 | 289 | 293 (70.77) | 83 (74.77) | TT vs. MM+MT | 0.406 | 509 | 376 | 133 (73.89) | 0.409 |
| Total               | 525 | 414 | 414 (100) | 111 (100) | MM vs. TT vs. DI | 0.573 | 712 | 532 | 180 (100) | 0.703 |
| M                   | 165 | 135 | 135 (63.00) | 30 (13.51) | M vs. T | 0.310 | 217 | 167 | 50 (13.89) | 0.410 |
| T                   | 885 | 722 | 693 (83.70) | 192 (86.49) | | 1207 | 897 | 310 (86.11) | |
| Total               | 1050 | 828 | 828 (100) | 222 (100) | | 1424 | 1064 | 360 (100) | |

Data are shown as n (percentage). *Derived from the χ^2 test. Obesity was defined as BMI value ≥ 25 kg/m^2 and normal BMI was defined as 18.5 kg/m^2 < BMI < 23 kg/m^2.

RAS: renin-angiotensin system; BMI: body mass index; DR: diabetic retinopathy; DNR: diabetic non-retinopathy; D: deletion; I: insertion; M: methionine; T: threonine; ACE: angiotensin converting enzyme; AGT: angiotensinogen.

Table 4. Association of RAS polymorphisms with hypertension and DR in patients with type 2 diabetes.

| Genotype and allele | Hypertensive patients with type 2 diabetes | | Normotensive patients with type 2 diabetes | |
|---------------------|------------------------------------------|---|--------------------------|---|
|                     | Total DNR | DR | Comparison | p^a | Total DNR | DR | Comparison | p^a |
| ACE DD              | 29 | 20 | 11.76 | 9 (41.7) | DD vs. DI+II | 0.375 | 137 | 104 | 33 (12.92) | 0.164 |
| DI                  | 115 | 68 | 40.00 | 47 (34.39) | DI vs. DD+II | 0.519 | 530 | 439 | 91 (34.80) | 0.056 |
| II                  | 133 | 82 | 48.24 | 51 (47.66) | II vs. DD+DI | 0.926 | 540 | 427 | 113 (47.68) | 0.310 |
| Total               | 277 | 170 | 170 (100) | 107 (100) | DD vs. DI vs. II | 0.621 | 1207 | 970 | 237 (100) | 0.115 |
| D                   | 173 | 108 | 31.76 | 65 (30.37) | D vs. I | 0.731 | 804 | 647 | 157 (33.12) | 0.925 |
| I                   | 381 | 232 | 68.24 | 149 (69.63) | | 1610 | 1293 | 317 (66.88) | |
| Total               | 554 | 340 | 340 (100) | 214 (100) | | 2414 | 1940 | 474 (100) | |
| AGT MM              | 4 | 2 | 1.49 | 2 (2.27) | MM vs. MT+TT | 0.669 | 26 | 23 | 3 (1.46) | 0.272 |
| MT                  | 57 | 33 | 24.63 | 24 (27.27) | MT vs. MM+TT | 0.659 | 268 | 221 | 47 (22.93) | 0.230 |
| TT                  | 161 | 99 | 73.88 | 62 (70.45) | TT vs. MM+MT | 0.576 | 728 | 573 | 155 (75.61) | 0.122 |
| Total               | 222 | 134 | 134 (100) | 88 (100) | MM vs. TT vs. MT | 0.815 | 1022 | 817 | 205 (100) | 0.231 |
| M                   | 65 | 37 | 37 (13.81) | 28 (15.91) | M vs. T | 0.540 | 320 | 267 | 53 (12.93) | 0.089 |
| T                   | 379 | 231 | 86.19 | 148 (84.09) | | 1724 | 1367 | 357 (87.07) | |
| Total               | 444 | 268 | 268 (100) | 176 (100) | | 2044 | 1634 | 410 (100) | |

Data are shown as n (percentage). *Derived from the χ^2 test.

RAS: renin-angiotensin system; DR: diabetic retinopathy; DNR: diabetic non-retinopathy; D: deletion; I: insertion; M: methionine; T: threonine; ACE: angiotensin converting enzyme; AGT: angiotensinogen.

polymorphisms of this gene are not a useful marker to assess susceptibility to DR. Otherwise, some discrepancy existed in studies by other researchers. Cheema et al. investigated the association and interaction between RAS gene polymorphisms and the development and progression of DR, which indicated RAS polymorphism was a significant risk factor both for nonproliferative DR and proliferative DR. Moreover, Nikzamir and co-authors have found that the D allele of the ACE gene is independently associated with retinopathy in Iranian T2DM patients. Hernández et al. reported the ACE I/D polymorphism was observed to be significantly associated with nonproliferative DR, but not with proliferative DR in a Pakistani population. Globocnik-Petrovic and colleagues thought that the ACE I/D gene polymorphism did not contribute to the genetic susceptibility to nonproliferative, proliferative or severe proliferative DR in a group of Caucasian T2DM individuals. We estimate that the possible reason for this
discrepancy in these results may be related to ethnic differences and lifestyle factors. A meta-analysis of larger numbers of patients regarding ACE I/D polymorphism on risk of DR was performed and found that ACE I/D gene polymorphism might contribute to DR development, especially in the Asian T2DM group. We speculate that the high heterogeneity in these results may lead to different outcomes in this study. Another meta-analysis was conducted to assess the relationship between the pattern of ACE gene polymorphism and T2DM patients’ presence or absence of retinopathy and found that the frequency of the DD genotype was not significantly different between the groups. Abhary et al. also conducted a meta-analysis and found no significant association between ACE polymorphisms and DR. The finding was consistent with our observations in this study.

In our study, we further assessed the ACE and AGT gene polymorphism with DR relating to obese and hypertensive patients. We have found that patients with normal BMI had similar RAS polymorphisms between the two groups relating to ACE genotype and AGT genotype, but in obese individuals, DR cases had a significantly higher frequency of DD genotype. Previous work reported that significant differences in FPG, DM duration, age, BMI, SBP, DBP and ACE activity existed between the DNR and DR groups. T2DM coexists with immunological disturbances and could lead to retinopathy. Therefore, clinical characteristics of T2DM patients such as obesity may interact with genetic factors for the development of retinopathy, as highlighted in a previous report. However, Pan et al. found that frequencies of the ACE genotypes (DD, ID and II) were not significant among the BMI-defined groups of Chinese patients with T2DM. In our study, regarding the outcome of binary logistic regression on the stratified BMI analyses after adjustment for covariates, no significant association between ACE and AGT gene polymorphisms and the risk of retinopathy in diabetes patients was found in all the comparisons, and the possible reasons were due to the small sample or others. Therefore, more attention should be paid to whether the ACE and AGT gene polymorphisms with the interaction of BMI facilitated the development of diabetes to DR.

Moreover, this study disclosed that no significant difference was displayed with respect to the frequency of ACE and AGT genotypes and alleles relating to the risk of DR in hypertensive and normotensive T2DM patients, suggesting that potential interactions of the RAS gene polymorphisms with blood pressure did not promote the pathogenesis of DR. Thomas et al. found no significant relationship was identified between these polymorphisms and blood pressure in a Chinese population relating to ACE and AGT genotypes. Zarouk and colleagues found that the DD genotype and the D allele of the ACE gene were associated with hypertension and T2DM in Egyptian patients. Ramachandran et al. discovered that the D allele of the ACE gene was associated with essential hypertension and T2DM in Malaysian individuals. Nakhjavani et al. concluded that the DD polymorphism in the ACE gene was independently associated with hypertension in Iranian type 2 diabetic patients. Xue and colleagues showed that the M allele of the AGT gene was probably related to hypertension in Chinese female T2DM patients. Zhou et al. predicted that ACE gene deletion is a risk factor for hypertension but is not a risk factor for diabetes in an elderly population. RAS is clearly involved in the maintenance of blood pressure and a significant relationship exists between blood pressure and retinopathy. Taken together, no significant difference in the ACE/AGT polymorphisms existed after adjusting for hypertension. The possible reasons may be due to the different ethnic groups, the diabetic control group with potential complications, small sample size or lower power value in some comparisons.

Some limitations should be noticed when interpreting our findings. Firstly, because of lack sufficient data, we were unable to perform further analysis of the relationship between RAS gene polymorphism and DR according to glycemic index, TG, HbA1c, duration of DM and so on. Secondly, the ACE2, AT1R and AT2R gene polymorphisms of the RAS system not further analyzed might play an

### Table 5. ORs of ACE/AGT genotypes for diabetic retinopathy in Chinese patients with type 2 diabetes.

|               | Model 1 | Model 2 | Model 3 | Model 4 |
|---------------|---------|---------|---------|---------|
| **ORs (95% CI)** | **p**   | **ORs (95% CI)** | **p**   | **ORs (95% CI)** | **p**   |
| **ACE**       |         |         |         |         |
| DD            | 0.974 (0.610–1.557) | 0.914 | 0.999 (0.621–1.609) | 0.998 | 0.968 (0.594–1.577) | 0.897 | 0.649 (0.160–2.633) | 0.545 |
| DI            | 0.842 (0.620–1.143) | 0.269 | 0.839 (0.614–1.147) | 0.271 | 0.821 (0.596–1.132) | 0.230 | 0.986 (0.481–2.020) | 0.970 |
| II            |         |         |         |         |
| AGT           |         |         |         |         |
| MM            | 0.633 (0.224–1.794) | 0.390 | 0.632 (0.210–1.903) | 0.415 | 0.648 (0.209–2.007) | 0.452 | 0.0         | 0.998 |
| MT            | 0.837 (0.600–1.166) | 0.292 | 0.837 (0.597–1.173) | 0.301 | 0.809 (0.574–1.142) | 0.228 | 1.220 (0.576–2.584) | 0.604 |
| TT            |         |         |         |         |

Model 1 adjusted for age, sex, age onset, duration of diabetes. Model 2 adjusted for model 1 + BMI, hypertension. Model 3 adjusted for model 2 + HbA1c, FPG, TG and TC. Model 4 adjusted for model 3 + plasma urea, plasma creatinine, ACR and AER.

ORs: odds ratios; ACE: angiotensin-converting enzyme; AGT: angiotensinogen; D: deletion; I: insertion; M: methionine; T: threonine; BMI: body mass index; Hb: hemoglobin; CI: confidence interval; FPG: fasting plasma glucose; TG: triglyceride; TC: total cholesterol; AER: albumin excretion rate.
important role in the relationship, which may influence our findings. Otherwise, the lower power values may also have influenced the findings. Even so, we hope that our findings may provide a line of evidence for further studies.

Conclusions

In summary, the results in this study indicate no significant association between ACE/AGT gene polymorphisms and DR in Chinese patients with T2DM; however, more investigations are needed to further prove our findings.

Acknowledgements

We would like to thank Chao-sheng Bo of Guilin Medical University for his statistical assistance.

Yong-chao Qiao designed the study, implemented the study protocol, collected and analyzed data and wrote the first manuscript. Min Wang directed statistical analyses of the data and designed the study. Min Wang, Yan-hong Pan, Xiao-xi Zhang, Fang Tian and Yin-ling Chen analyzed and interpreted the data. Hai-lu Zhao designed the study and revised the manuscript. All authors contributed to the discussion, reviewed and edited the manuscript, and approved the final manuscript.

ORCID iD

Yong-chao Qiao. https://orcid.org/0000-0003-4877-899X.

Declaration of conflicting interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (grant numbers 81270934, 81471054).

References

1. Globocnik-Petrovic M, Hawlina M, Peterlin B, et al. Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes. Ophthalmologica 2003; 217: 219–224.
2. Fong DS, Aiello LP, Ferris FL 3rd, et al. Diabetic retinopathy. Diabetes Care 2004; 27: 2540–2553.
3. Zhang W, Liu H, Al-Shabrawey M, et al. Inflammation and diabetic retinal microvascular complications. J Cardiovasc Dis Res 2011; 2: 96–103.
4. Klein R, Klein BE, Moss SE, et al. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994; 154: 2169–2178.
5. Leslie RD and Pyke DA. Diabetic retinopathy in identical twins. Diabetes 1982; 31: 19–21.
6. Gutiérrez C, Vendrell J, Pastor R, et al. Angiotensin I-converting enzyme and angiotensinogen gene polymorphisms in non-insulin-dependent diabetes mellitus. Lack of relationship with diabetic nephropathy and retinopathy in a Caucasian Mediterranean population. Metabolism 1997; 46: 976–980.
7. Taverna MJ, Sola A, Guyot-Argentont C, et al. eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy. Diabet Med 2002; 19: 240–245.
8. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51: 1635–1639.
9. Demaine A, Cross D and Millward A. Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci 2000; 41: 4064–4068.
10. Heesom AE, Hibberd ML, Millward A, et al. Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes 1997; 46: 287–291.
11. Rahimi Z, Moradi M and Nasri H. A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy. J Res Med Sci 2014; 19: 1090–1098.
12. Thomas GN, Tomlinson B, Chan JC, et al. Renin-angiotensin system gene polymorphisms, blood pressure, dyslipidemia, and diabetes in Hong Kong Chinese: A significant association of the ACE insertion/deletion polymorphism with type 2 diabetes. Diabetes Care 2001; 24: 356–361.
13. Zeng R, Wang QP, Fang MX, et al. Association of A-20C polymorphism in the angiotensinogen gene with essential hypertension: A meta-analysis. Genet Mol Res 2015; 14: 12984–12992.
14. Vassalli JD, Sappino AP and Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067–1072.
15. Ohno T, Kawazu S and Tomono S. Association analyses of the polymorphisms of angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics. Metabolism 1996; 45: 218–222.
16. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343–1346.
17. Saleem S, Azam A, Maqsood SI, et al. Role of ACE and PAI-1 polymorphisms in the development and progression of diabetic retinopathy. Plos One 2015; 10: e0144557.
18. Cheema BS, Kohli HS, Sharma R, et al. Angiotensin-converting enzyme gene variants interact with the renin-angiotensin system pathway to confer risk and protection against type 2 diabetic retinopathy. J Diabetes Investig 2013; 4: 103–104.
19. Yildiz M, Karkucak M, Yakut T, et al. Lack of association of genetic polymorphisms of angiotensin-converting enzyme gene I/D and glutathione-S-transferase enzyme T1 and M1 with retinopathy of prematures. Genet Mol Res 2010; 9: 2131–2139.
20. Wang M, Zhang X, Song X, et al. Nodular glomerulosclerosis and renin angiotensin system in Chinese patients with type 2 diabetes. Mol Cell Endocrinol 2016; 427: 92–100.
20. Zhao HL, Tong PC, Lai FM, et al. Association of glomerulopathy with the 5'-end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients. *Diabetes* 2004; 53: 2984–2991.

21. Cheung CY, Hui EY, Lee CH, et al. Impact of genetic loci identified in genome-wide association studies on diabetic retinopathy in Chinese patients with type 2 diabetes. *Invest Ophthalmol Vis Sci* 2016; 57: 5518–5524.

22. WHO Expert Consultation. Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* 2004; 363: 157–163.

23. Cathrotia RG, Paralikar SJ, Rao PV, et al. Impact of different grades of body mass index on left ventricular structure and function. *Indian J Physiol Pharmacol* 2010; 54: 149–156.

24. Dupont WD and Plummer WD Jr. Power calculations for matched case-control studies. *Biometrics* 1988; 44: 1157–1168.

25. Dupont WD. Power calculations for matched case-control studies. *Control Clin Trials* 1990; 11: 116–128.

26. Dupont WD. Power calculations for matched case-control studies. *Biometrics* 1988; 44: 1157–1168.

27. Liao L, Lei MX, Chen HL, et al. Angiotensin converting enzyme gene polymorphism and type 2 diabetic nephropathy [article in Chinese]. Zhong Nan Da Xue Xue Bao Yi Xue Ban [Journal of Central South University Medical Sciences] 2004; 29: 410–413.

28. Nikzamir A, Rashidi A, Esteghamati A, et al. The relation between angiotensin-converting enzyme insertion/deletion polymorphism and proliferative diabetic retinopathy. *Aldosterone Syst* 2010; 2016: 7420540.

29. Nakhjavani M, Esfahanian F, Jahanshahi A, et al. The relationship between the insertion/deletion polymorphism of angiotensin-converting enzyme gene and hypertension in Iranian patients. *Diabetes, Obesity and Metabolism* 2011; 13: 622–627.

30. Nakhjavani M, Esfahanian F, Jahanshahi A, et al. The relationship between the insertion/deletion polymorphism of angiotensin-converting enzyme gene I/D poly...